Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Czech Republic.
Department of Psychiatry, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic.
Schizophr Res. 2020 Apr;218:85-92. doi: 10.1016/j.schres.2020.02.004. Epub 2020 Feb 20.
We aimed to validate the Czech version of the MATRICS Consensus Cognitive Battery (MCCB). The MCCB is a test battery designed to assess cognitive treatment effects in clinical trials of patients with schizophrenia. The valid, reliable and replicable measurement of cognition in schizophrenia is of substantial importance for such clinical trial studies. We performed a psychometric analysis of the MCCB composite and domain scores based on ROC analysis of 67 schizophrenia patients and 67 age- and education-matched healthy controls from a total sample of 220 controls. Also, we correlated MCCB variables with scales measuring psychosocial functioning (Personal and Social Performance scale; PSP). The internal consistency of all 10 tests in the MCCB battery was good (Cronbach's α = 0.85 (95% CI [0.83, 0.88])). The discriminative validity for the detection of neurocognitive dysfunction in schizophrenia based on the area under the curve of MCCB composite T-score was ≥90% (95% CI [0.85, 0.96]) and all MCCB domains showed ps < .001. The MCCB global composite and the Speed of Processing domain score significantly predicted the PSP ratings. A confirmatory factor analysis on the whole control sample (N = 220) showed an optimal fit for a 6-factor in comparison to 1-factor solution. In conclusion, we found high discriminative validity for the Czech MCCB version, similar to the differentiation of schizophrenia versus healthy control groups in the original MCCB studies. We also established the factorial validity of the MCCB and showed that the overall composite of the MCCB predicts psychosocial functioning in the patient group.
我们旨在验证捷克版 MATRICS 共识认知电池(MCCB)。MCCB 是一种用于评估精神分裂症患者临床试验中认知治疗效果的测试电池。对于此类临床试验研究,精神分裂症认知的有效、可靠和可重复测量具有重要意义。我们对 220 名对照组中的 67 名精神分裂症患者和 67 名年龄和教育程度匹配的健康对照者进行了 MCCB 复合和域评分的心理测量分析。此外,我们还将 MCCB 变量与测量心理社会功能的量表(个人和社会表现量表;PSP)进行了相关性分析。MCCB 电池中所有 10 项测试的内部一致性均较好(Cronbach's α=0.85(95%CI [0.83, 0.88]))。基于 MCCB 复合 T 评分曲线下面积,MCCB 对精神分裂症神经认知功能障碍的鉴别效度≥90%(95%CI [0.85, 0.96]),且所有 MCCB 域均显示 ps<0.001。MCCB 总体复合和处理速度域评分显著预测 PSP 评分。对整个对照组样本(N=220)进行的验证性因子分析表明,与 1 因素解决方案相比,6 因素解决方案具有最佳拟合度。总之,我们发现捷克 MCCB 版本具有较高的鉴别效度,与原始 MCCB 研究中精神分裂症与健康对照组的区分相似。我们还确定了 MCCB 的因子有效性,并表明 MCCB 的总体综合预测了患者组的心理社会功能。